MX9707944A - Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them. - Google Patents
Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them.Info
- Publication number
- MX9707944A MX9707944A MX9707944A MX9707944A MX9707944A MX 9707944 A MX9707944 A MX 9707944A MX 9707944 A MX9707944 A MX 9707944A MX 9707944 A MX9707944 A MX 9707944A MX 9707944 A MX9707944 A MX 9707944A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- immunogenic
- making
- oligosaccharide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention provides immunogenic oligosaccharide compositions and methods of making and using them. In particular, the compositions comprise oligosaccharides covalently coupled to carrier protein, wherein the resultant conjugate has been shown to contain specific immunogenic epitopes and elicits a protectively immunogenic response. This invention also provides compositions comprising an oligosaccharide of S. pneumoniae serotype 8 useful for stimulating an immune response to an antigen, methods of providing protective immunization against a bacterial pathogen using these compositions, methods of augmenting an immunogenic response to an antigen by administering these S. pneumoniae serotype 8 oligosaccharide compositions along with the antigen, and methods of making the immunostimulatory compositions described above.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/477,497 US5866132A (en) | 1995-06-07 | 1995-06-07 | Immunogenic oligosaccharide compositions |
US08/482,626 US5695768A (en) | 1995-06-07 | 1995-06-07 | Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides |
CA002153730A CA2153730A1 (en) | 1995-07-12 | 1995-07-12 | Immunostimulating activity of streptococcus pneumoniae serotype 8 oligosaccharides |
CA002153733A CA2153733A1 (en) | 1995-07-12 | 1995-07-12 | Immunogenic oligosaccharide compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9707944A true MX9707944A (en) | 1998-06-30 |
Family
ID=27427244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9707944A MX9707944A (en) | 1995-06-07 | 1997-10-15 | Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them. |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0831894A1 (en) |
JP (1) | JPH11506110A (en) |
KR (1) | KR19990007777A (en) |
AU (1) | AU725279B2 (en) |
CZ (1) | CZ327897A3 (en) |
IL (1) | IL121585A0 (en) |
MX (1) | MX9707944A (en) |
NO (1) | NO974727L (en) |
NZ (1) | NZ309713A (en) |
WO (1) | WO1996040225A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT939647E (en) | 1996-08-27 | 2002-04-29 | Chiron Corp | GLYCONPONES OF NEISSERIA MENINGITIDIS SEROGRUPO B AND METHODS OF USE OF THE SAME |
NZ502437A (en) * | 1997-07-17 | 2001-11-30 | Baxter Healthcare Sa | Immunogenic conjugates comprising H. influenzae type b (Hib) polysaccharide-recombinant refolded meningococcal outer membrane protein (rPorB) conjugate |
US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
AU760669B2 (en) | 1998-04-28 | 2003-05-22 | Galenica Pharmaceuticals, Inc. | Polysaccharide-antigen conjugates |
US6436653B1 (en) | 1998-12-15 | 2002-08-20 | Exiqon A/S | Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces |
NZ553554A (en) * | 2000-06-20 | 2008-11-28 | Id Biomedical Corp | Streptococcus antigens |
BRPI1011753B8 (en) * | 2009-06-22 | 2021-05-25 | Wyeth Llc | immunogenic conjugates of capsular polysaccharide from staphylococcus aureus serotypes 5 and 8, their use and compositions comprising them |
EP2870974A1 (en) * | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
US9492559B2 (en) * | 2014-01-21 | 2016-11-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
CA2961694C (en) * | 2014-09-26 | 2022-11-01 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Vaccines against streptococcus pneumoniae serotype 8 |
EP3000820A1 (en) * | 2014-09-26 | 2016-03-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synthetic vaccines against Streptococcus pneumoniae serotype 8 |
US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
EP3493837B1 (en) | 2016-08-05 | 2022-08-31 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
CN109890415B (en) | 2016-08-05 | 2023-04-04 | 圣诺菲·帕斯图尔公司 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
JP2020533299A (en) * | 2017-09-07 | 2020-11-19 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Formulation method of Streptococcus pneumoniae polysaccharide for conjugation to carrier protein |
CA3087572A1 (en) | 2018-02-05 | 2019-08-08 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
MX2020008198A (en) | 2018-02-05 | 2020-09-22 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition. |
BR112020021296A2 (en) | 2018-04-18 | 2021-01-26 | Sk Bioscience Co., Ltd. | capsular polysaccharide of streptococcus pneumoniae and its immunogenic conjugate |
EP3893926A1 (en) * | 2018-12-12 | 2021-10-20 | Pfizer Inc. | Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof |
CN113607939A (en) * | 2021-08-05 | 2021-11-05 | 艾美探索者生命科学研发有限公司 | Method for measuring adsorption rate of various combined stock solutions of pneumococcal polysaccharide combined vaccine |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1187753B (en) * | 1985-07-05 | 1987-12-23 | Sclavo Spa | GLYCOPROTEIC CONJUGATES WITH TRIVALENT IMMUNOGENIC ACTIVITY |
DE3750139T2 (en) * | 1986-04-16 | 1994-10-06 | Brigham & Womens Hospital | BACTERIAL ANTIGENS, ANTIBODIES, VACCINE AND THEIR PRODUCTION. |
US5153312A (en) * | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
JP2948315B2 (en) * | 1990-12-18 | 1999-09-13 | ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ ワシントン | Dialysate generation system with dialysate pellets |
CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
CA2059693C (en) * | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Polysaccharide antigens from streptococcus pneumoniae |
-
1996
- 1996-06-06 AU AU59944/96A patent/AU725279B2/en not_active Ceased
- 1996-06-06 KR KR1019970707283A patent/KR19990007777A/en not_active Application Discontinuation
- 1996-06-06 NZ NZ309713A patent/NZ309713A/en unknown
- 1996-06-06 WO PCT/CA1996/000387 patent/WO1996040225A1/en not_active Application Discontinuation
- 1996-06-06 JP JP9500049A patent/JPH11506110A/en not_active Ceased
- 1996-06-06 EP EP96917311A patent/EP0831894A1/en not_active Withdrawn
- 1996-06-06 CZ CZ973278A patent/CZ327897A3/en unknown
- 1996-06-06 IL IL12158596A patent/IL121585A0/en unknown
-
1997
- 1997-10-13 NO NO974727A patent/NO974727L/en not_active Application Discontinuation
- 1997-10-15 MX MX9707944A patent/MX9707944A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU725279B2 (en) | 2000-10-12 |
WO1996040225A1 (en) | 1996-12-19 |
NO974727L (en) | 1997-12-08 |
CZ327897A3 (en) | 1998-02-18 |
AU5994496A (en) | 1996-12-30 |
KR19990007777A (en) | 1999-01-25 |
EP0831894A1 (en) | 1998-04-01 |
JPH11506110A (en) | 1999-06-02 |
NO974727D0 (en) | 1997-10-13 |
NZ309713A (en) | 1999-11-29 |
IL121585A0 (en) | 1998-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9707944A (en) | Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them. | |
AU8483391A (en) | Improved oligosaccharide conjugate vaccines | |
GR3035081T3 (en) | Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections | |
GB9713156D0 (en) | Vaccines | |
WO2000056360A3 (en) | Vaccine against antigens from bacteriae | |
ES8707861A1 (en) | Immunogenic conjugates of E. coli LT-B enterotoxin subunit and capsular polymers. | |
WO1999055730A3 (en) | Polyepitope carrier protein | |
AU3065489A (en) | T-cell epitope as carriers molecule for conjugate vaccines | |
HK1041825A1 (en) | A polysaccharide-protein conjugate or oligosaccharide-protein conjugate, a method for producing the same, and its uses thereof | |
EP0866133A3 (en) | A group b streptococcus vaccine | |
HUT50048A (en) | Process for producing streptococcus protein antigen and pharmaceutical compositions comprising same | |
CA2145397A1 (en) | Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines | |
AU6832398A (en) | Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof | |
WO1999052548A3 (en) | Conjugate vaccines for the prevention of dental caries | |
CA2139217A1 (en) | Vaccine composition for eliciting an immune response against n-glycolylated gangliosides and its use for cancer treatment | |
NZ331557A (en) | Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis | |
AU1991097A (en) | Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases | |
NZ500151A (en) | A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence | |
AU3991899A (en) | Verotoxin b subunit for immunization | |
DE69535059D1 (en) | Borrelia burgdorferi bacterin | |
CA2133108A1 (en) | Pasteurella haemolytica type a-1 bacterin-toxoid vaccine | |
Michon et al. | Combination conjugate vaccines against multiple serotypes of group B streptococci | |
AU2579600A (en) | Product and method for obtaining specific immunisation with one or more antigens | |
WO1990015132A3 (en) | Cloned treponema hyodysenteriae endoflagellar antigen | |
NZ337730A (en) | use of an oligosaccharide hapten- carrier conjugate for immunizing against a bacterial or viral pathogen by administering |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
MM | Annulment or lapse due to non-payment of fees |